Literature DB >> 21636177

[Validity and usefulness of B-type natriuretic peptide (BNP) for early detection of left ventricular dysfunction in high-risk patients in primary care].

José M Lobos Bejarano1, Cristina Horrillo García, Ana I González-González, Angel Castellanos Rodríguez, Santiago Díaz Sánchez, Javier Castellanos Maroto, Ricardo Rodriguez-Barrientos, Miguel A García-Fernández.   

Abstract

OBJECTIVE: The aim of this study was to determine the accuracy of BNP test for early diagnosis of left ventricular dysfunction in patients at high-risk for heart failure.
DESIGN: Cross-sectional descriptive study.
SETTING: 7 Primary Care Centres in Madrid (Spain). PARTICIPANTS: A consecutive sample of 204 consecutive asymptomatic patients with high risk for heart failure (Stages A-B, AHA/ACC Classification). MAIN MEASUREMENTS: BNP plasma levels were measured in the clinical setting using Triage BNP Test(®) (Biosite(®)) and an echocardiography was performed in the following 3 days in a single hospital unit as a reference standard. Plasma BNP levels were compared depending on the presence/absence of left ventricular dysfunction (LVD), type and severity degree. Sensitivity, specificity, positive and negative predictive values, and Área under the receiver operating characteristic curve (ROC) for BNP assay were calculated.
RESULTS: BNP values were significantly higher (P<.001) in patients with left ventricular systolic dysfunction (LVSD). No significant differences were found for diastolic dysfunction. The best cut-off value to discriminate the patients with LVSD was 71.00 pg/ml, with an Área under the ROC curve of 0.757 (95% CI 0.64-0.87). Sensitivity for LVD diagnosis was 75% (95% CI 50.66-99.34), specificity 70.19% (95% CI 62.81-77.57), positive predictive value (PPV) 20% (95% CI 9.05-30.95), and negative predictive value (NPV) 96.58% (95% CI 92.86-100), with LVSD prevalence of 9.04% in this population.
CONCLUSIONS: BNP determinations are of value in diagnosing LVSD in a primary care setting, with similar sensitivities and specificities. Due to the high NPV is useful to rule-out patients for echocardiography.
© 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21636177      PMCID: PMC7025147          DOI: 10.1016/j.aprim.2010.12.009

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  21 in total

Review 1.  [Evidence based medical treatment of heart failure].

Authors:  A Agustí Escasany; M Durán Dalmau; J M Arnau De Bolós; D Rodríguez Cumplido; E Diogène Fadini; J Casas Rodríguez; E Galve Basilio; N Manito Lorite
Journal:  Rev Esp Cardiol       Date:  2001-06       Impact factor: 4.753

Review 2.  [The circulating NTproBNP level, a new biomarker for the diagnosis of heart failure in patients with acute shortness of breath].

Authors:  Antoni Bayés-Genís
Journal:  Rev Esp Cardiol       Date:  2005-10       Impact factor: 4.753

3.  [Cardiac failure. The perspective today from family medicine].

Authors:  J M Lobos Bejarano
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

4.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.

Authors:  L Katherine Morrison; Alex Harrison; Padma Krishnaswamy; Radmila Kazanegra; Paul Clopton; Alan Maisel
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

5.  Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population.

Authors:  A Luchner; J C Burnett; M Jougasaki; H W Hense; I M Heid; F Muders; G A Riegger; H Schunkert
Journal:  J Hypertens       Date:  2000-08       Impact factor: 4.844

6.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

7.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.

Authors:  M R Cowie; A D Struthers; D A Wood; A J Coats; S G Thompson; P A Poole-Wilson; G C Sutton
Journal:  Lancet       Date:  1997-11-08       Impact factor: 79.321

8.  The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study.

Authors:  Irene Betti; Gabriele Castelli; Alessandro Barchielli; Cinzia Beligni; Vittorio Boscherini; Leonardo De Luca; Gianni Messeri; Mihai Gheorghiade; Alan Maisel; Alfredo Zuppiroli
Journal:  J Card Fail       Date:  2009-01-21       Impact factor: 5.712

9.  High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): implications for heart failure screening programs.

Authors:  Marc A Silver; Carol Pisano
Journal:  Congest Heart Fail       Date:  2003 May-Jun

10.  Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.

Authors:  Ramachandran S Vasan; Emelia J Benjamin; Martin G Larson; Eric P Leip; Thomas J Wang; Peter W F Wilson; Daniel Levy
Journal:  JAMA       Date:  2002-09-11       Impact factor: 56.272

View more
  1 in total

1.  [Situations where natriuretic peptides may be useful].

Authors:  Javier Jacob; Francisco Javier Martín-Sanchez; Pablo Herrero; Oscar Miró; Pere Llorens
Journal:  Aten Primaria       Date:  2012-09-08       Impact factor: 1.137

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.